Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study

BACKGROUND: In the LATTE study, daily oral cabotegravir + rilpivirine demonstrated higher rates of efficacy than efavirenz + 2 nucleoside reverse-transcriptase inhibitors (NRTIs) through Week 96 in antiretroviral therapy (ART)-naive adults with human immunodeficiency virus (HIV)-1. We present the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutton, Kenneth C, De Vente, Jerome, Leblanc, Roger, Dejesus, Edwin, Smith, Graham, Mills, Anthony, Baril, Jean-Guy, St. Clair, Marty, Stancil, Britt S, Vandermeulen, Kati, Spreen, William R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946678/
https://www.ncbi.nlm.nih.gov/pubmed/35350172
http://dx.doi.org/10.1093/ofid/ofac067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946678/
https://www.ncbi.nlm.nih.gov/pubmed/35350172
http://dx.doi.org/10.1093/ofid/ofac067

Ejemplares similares